Clinical characteristics and outcomes of pediatric methylphenidate intoxication: a five-year single-center study Authors: Pırıl Yıldız, Ali Yurtseven, Caner Turan, Burcu Vural Atalay, Eylem Ulas Saz Published: 2026 ABSTRACT AbstractBackgroundMethylphenidate is widely prescribed for attention-deficit/hyperactivity disorder, and its use has increased substantially in recent years. Although generally considered safe within therapeutic ranges, supratherapeutic ingestion may result in various systemic adverse effects. This study aimed to evaluate the demographic and clinical characteristics of children presenting with overdose ingestion and to identify potential factors associated with symptom development.MethodsWe conducted a retrospective review of patients younger than 18 years who presented to a tertiary pediatric emergency department between January 1, 2020, and December 31, 2024, due to overdose ingestion. Demographic characteristics, psychiatric history, ingested dose, mode of exposure, clinical findings, emergency department course, and factors potentially associated with adverse effects were analyzed.ResultsThirty-two patients were included; 72% were female, and ingestion was intentional in 84%. The mean ingested dose was 5.7 mg/kg. Clinical symptoms developed in 41% of patients. The most frequent findings were tachycardia (38%), mild hypertension (34%), agitation (22%), and seizures (16%). Although most cases were mild and resolved within 12 h of observation, one toddler developed neuropsychiatric manifestations requiring close monitoring with full recovery within 48 h. No statistically significant association was observed between age, sex, gastrointestinal decontamination status, or reported ingested dose and the development of clinical symptoms (p > 0.05).ConclusionsPediatric methylphenidate intoxication is generally mild, but severe neuropsychiatric and cardiovascular effects may occur. Careful clinical monitoring remains essential.Trial registrationNot applicable.Keywords: Children, Methylphenidate, Poisoning, Overdose, Pediatric emergency, Stimulant toxicity Background Attention-deficit/hyperactivity disorder (ADHD) is among the most prevalent neurodevelopmental disorders in childhood, affecting approximately 8% of children in the USA [1]. Pharmacologic treatment remains a cornerstone of ADHD management, and stimulant medications are prescribed to millions of children worldwide each year [2]. Among these agents, methylphenidate (MPH) is one of the most frequently used psychostimulants in pediatric populations [1, 2].In recent decades, the expanding therapeutic use of MPH has paralleled a steady increase in reported exposures and overdoses [3, 4]. Adolescents more commonly present with intentional ingestions, including suicide attempts and misuse, whereas younger children typically experience accidental exposures related to exploratory behavior [4]. Although MPH is generally considered safe and well tolerated within therapeutic dose ranges, supratherapeutic ingestion may lead to sympathomimetic toxicity involving primarily the central nervous and cardiovascular systems [5]. Reported clinical manifestations include agitation, irritability, hallucinations, tachycardia, hypertension, and, in severe cases, seizures, hyperthermia, and cardiac dysrhythmias [6]. Large poison center–based studies have demonstrated that most pediatric MPH exposures are asymptomatic or result in only minor clinical effects [4–7]. Despite the generally favorable prognosis reported in national poison center data, real-world clinical presentations may vary according to age, intent of ingestion, psychiatric comorbidity, and ingested dose [5–8]. Furthermore, detailed single-center clinical data evaluating symptom patterns, short-term outcomes, and factors associated with adverse effects remain limited. Better characterization of these cases is essential to guide emergency department management and risk stratification. The present study aimed to evaluate the demographic and clinical characteristics of pediatric patients presenting with overdose methylphenidate ingestion, to describe the spectrum of adverse effects observed, and to identify potential factors associated with the development of clinical symptoms. Materials and methods Aim, design and setting This single-center retrospective observational study was conducted at the Pediatric Emergency Department of Ege University Faculty of Medicine, a tertiary care university hospital in Izmir, Turkey. The hospital serves as a regional referral center for pediatric emergency cases. All patients under 18 years of age who presented to the Pediatric Emergency Department between January 1, 2020, and December 31, 2024, with suspected MPH intoxication were eligible for inclusion. Patient selection, data collection and clinical management A total of 39 pediatric and adolescent cases of overdose MPH ingestion were identified during the study period. Three cases were excluded due to insufficient data in the medical records, and four cases were excluded because of co-ingestion of other medications or substances. The final study population consisted of 32 patients with isolated MPH intoxication, all of whom had ingested at least 2 mg/kg of methylphenidate, a threshold previously recommended for medical evaluation following acute methylphenidate exposure [3–5]. All patients were managed according to standard pediatric toxicology protocols in our department [9, 10]. Patients presenting within one hour of ingestion underwent gastrointestinal decontamination with gastric lavage and activated charcoal when clinically indicated and in the absence of contraindications. Supportive care and close clinical monitoring were provided in all cases, and treatment was individualized according to symptom severity. All patients with intentional self-harm and substance misuse underwent consultation with the child and adolescent psychiatry service. Patients with a history of co-ingestion of other medications or substances were excluded to allow evaluation of the isolated toxic effects of MPH. Patients were categorized into two age groups (≤ 12 years and > 12 years) for comparative analyses, reflecting the distinction between preadolescent children and adolescents in patterns of exposure and clinical presentation. In our emergency department, the severity of poisoning cases is routinely assessed according to the outcome severity definitions recommended by the American Association of Poison Control Centers (AAPCC) [11]. Accordingly, poisoning severity was determined through review of the medical records and classified according to the most severe manifestations documented during emergency department observation and hospitalization. Mild toxicity was defined as transient symptoms that resolved spontaneously or required only observation (e.g., tachycardia, mild hypertension, mydriasis, or mild agitation). Moderate toxicity was defined as more pronounced or prolonged symptoms requiring pharmacological treatment or extended observation, such as persistent agitation requiring medication, prolonged tachycardia or hypertension necessitating continued monitoring, or short seizures that resolved spontaneously without recurrence. Severe toxicity was defined as clinically significant manifestations associated with substantial morbidity, including delirium, severe agitation requiring continuous sedation, seizures requiring pharmacological treatment, significant cardiovascular instability, or intensive care unit admission. In our institution, asymptomatic patients with isolated methylphenidate intoxication were routinely observed for approximately 12 h. Symptomatic patients were monitored until complete resolution of clinical findings and achievement of clinical stability. Decisions regarding the duration of observation and discharge were made by the treating physician based on symptom progression and overall clinical status. Statistical analysis Collected data were summarized using descriptive statistics. Exploratory comparisons between subgroups were performed. Categorical variables were analyzed using the chi-square or Fisher’s exact test, as appropriate. Continuous variables were assessed for normality and are presented as mean ± standard deviation or median (interquartile range) according to distribution characteristics. As the distribution of ingested dose was non-normal, it was summarized as median (IQR) and compared between groups using the Mann–Whitney U test. A p-value < 0.05 was considered statistically significant. As this study was retrospective and descriptive in nature and did not involve a pre-specified hypothesis testing framework, no a priori sample size or power calculation was performed. Ethical approval The study was approved by the Ege University Medical Research Ethics Committee (approval number: 25-3T/55). Due to the retrospective design of the study and the use of anonymized data, the requirement for informed consent was waived. The study was conducted in accordance with the principles of the Declaration of Helsinki. Results The study included 32 patients with a median age of 15 years (range, 2–17 years); 72% (n = 23) were female. Seven patients (21.9%) were aged ≤ 12 years, while 25 patients (78.1%) were aged > 12 years. The majority of patients had a pre-existing psychiatric diagnosis, most commonly ADHD (66%, n = 21). Major depressive disorder was present in 12% (n = 4), and bipolar disorder in 6% (n = 2). A pre-existing psychiatric diagnosis was present in six of seven patients (85.7%) aged ≤ 12 years and in 15 of 25 patients (60%) aged > 12 years, with no statistically significant difference between age groups. Twenty-seven patients (84%, n = 27) had intentional ingestion, including 24 suicide attempts (75%) and three cases of substance misuse (9%), whereas five cases (16%, n = 5) were classified as accidental exposures. Intent of ingestion differed significantly according to age group (P = 0.003). Among patients aged ≤ 12 years, accidental ingestion (n = 4) and suicide attempts (n = 3) occurred at similar frequencies. In contrast, patients older than 12 years were significantly more likely to present with intentional ingestion, including 21 suicide attempts and three cases of substance misuse, with only one accidental exposure. The overall median ingested dose was 4.5 (mg/kg) (range: 2–14 (mg/kg)). Age-based comparison demonstrated similar median doses between patients aged ≤ 12 years and those aged > 12 years (6.0 [IQR: 9] vs. 4.0 [IQR: 4] (mg/kg), P = 0.873). During emergency department observation, 59% (n = 19) of patients remained asymptomatic, while 41% (n = 13) developed clinical symptoms. The most frequently observed findings were tachycardia (38%, n = 12), hypertension (34%, n = 11), agitation (22%, n = 7), mydriasis (19%, n = 6), seizures (16%, n = 5), self-reported palpitations (9%, n = 3), and altered mental status with severe agitation (3%, n = 1). Clinical symptoms were observed in three of seven patients (42.9%) in the ≤ 12-year group and in 10 of 25 patients (40.0%) in the > 12-year group, with no statistically significant difference between groups. The demographic and clinical characteristics of the patients according to age group are summarized in Table 1. Table 1Demographic and clinical characteristics of patients according to age groupVariablesPatients aged ≤12 years n = 7 (21.9%)Patients aged >12 years n = 25 (78.1%)p-valueSex (Female), n (%)5 (71)18 (72)0.976bPre-existing psychiatric diagnosis, n (%)6 (85.7)15 (60)0.374bIntent of ingestion, n (%) 0.003 b* Accidental Intentional self-harm Misuse / abuse4 (57)3 (43)-1 (4)21 (84)3 (12)Clinical Symptoms - present, n (%)3 (43)10 (40)0.892bIngested dose (mg/kg), median (IQR)6 (9)4 (4)0.873aGastrointestinal decontamination n (%)0.669b Performed Not performed3 (43)4 (57)13 (52)12 (48)Hospitalization, n (%)0.296b Admitted Discharged2 (28)5 (72)3 (12)22 (88)aMann–Whitney U test; bFisher’s exact test; *p < 0.05 considered statistically significant; IQR = Interquartile Range Demographic and clinical characteristics of patients according to age group Accidental Intentional self-harm Misuse / abuse 4 (57) 3 (43) - 1 (4) 21 (84) 3 (12) Performed Not performed 3 (43) 4 (57) 13 (52) 12 (48) Admitted Discharged 2 (28) 5 (72) 3 (12) 22 (88) aMann–Whitney U test; bFisher’s exact test; *p < 0.05 considered statistically significant; IQR = Interquartile Range None of the patients with hypertension required specific antihypertensive therapy, and all cases resolved spontaneously during clinical observation. Two patients with persistent agitation required benzodiazepine administration, with subsequent resolution of symptoms. Regarding seizures, four patients experienced brief, self-limited episodes that resolved spontaneously without recurrence and only one patient required pharmacological treatment for seizure control. Overall, supportive care and close clinical monitoring were sufficient for the management of the vast majority of patients. According to the severity classification, 6 patients (19%) were classified as having mild toxicity, 5 (16%) as moderate toxicity, and 2 (6%) as severe toxicity. Among the five patients classified as having moderate toxicity, two experienced short seizures that resolved spontaneously without recurrence. Two additional patients had short self-limited seizures accompanied by prolonged tachycardia requiring extended observation. The remaining patient experienced prolonged tachycardia, prolonged hypertension, and persistent agitation requiring pharmacological treatment and extended monitoring. One of the patients with severe toxicity was a 16-year-old adolescent who intentionally ingested approximately 7 mg/kg of methylphenidate and presented with a seizure requiring pharmacological treatment. The patient recovered completely during observation and was discharged without complications. The second patient with severe toxicity was a 2-year-old girl who accidentally ingested approximately 4 mg/kg of extended-release MPH and developed altered mental status characterized by severe agitation, irritability, and confusion, accompanied by significant cardiovascular manifestations, including marked tachycardia (up to 200 beats/min) and hypertension (up to 140/104 mmHg). Laboratory evaluation revealed transient elevation of cardiac biomarkers (CK-MB: 119 U/L; Troponin T: 0.22 ng/mL). The patient was managed with supportive care and close monitoring; clinical findings gradually resolved, and cardiac biomarkers normalized within 48 h. She was discharged without complications. Gastrointestinal decontamination with gastric lavage and activated charcoal was performed in 50% (n = 16) of patients. Clinical symptoms developed in 5 of 16 patients (31.3%) who underwent decontamination and in 8 of 16 patients (50.0%) who did not undergo decontamination (Table 2). Table 2Factors associated with clinical symptom developmentVariablesSymptoms present (n = 13)No symptoms (n = 19)P-valueSex (Female), n (%)8 (62)15 (79)0.427bAge (years), median (IQR)15 (4)16 (2)0.409aIngested dose (mg/kg), median (IQR)7 (6)4 (3)0.160aTime from ingestion to ED presentation (hours), median (IQR)1(1–2)2 (1–7.25)0.179aGastrointestinal decontamination n (%)PerformedNot performed5 (38)8 (62)11 (58)8 (42)0.280aMann–Whitney U test; bFisher’s exact test; ED = Emergency Department; IQR = Interquartile Range Factors associated with clinical symptom development Performed Not performed 5 (38) 8 (62) 11 (58) 8 (42) aMann–Whitney U test; bFisher’s exact test; ED = Emergency Department; IQR = Interquartile Range No statistically significant association was identified between age, sex, ingested dose or time from ingestion to emergency department presentation and the development of clinical symptoms (Table 2). In the majority of cases (88%, n = 28), symptoms resolved within 12 h without the need for specific pharmacological intervention. In four patients (12%), mild symptoms persisted beyond 24 h, with the longest duration extending to 48 h; in all cases, symptoms resolved completely under supportive care. No permanent complications or mortality were observed. Discussion In this single-center retrospective study including thirty two pediatric patients with MPH overdose, the majority of cases were mild and self-limited. More than half of the patients remained asymptomatic, and among symptomatic individuals, cardiovascular findings such as tachycardia and mild hypertension predominated. These results are consistent with large poison center–based studies demonstrating that most pediatric methylphenidate exposures result in either no symptoms or minor clinical effects [4–8]. Despite increasing prescription rates of stimulant medications worldwide, most pediatric patients with isolated MPH ingestion experience a favorable clinical course [12–15]. A high proportion of intentional ingestions was observed in our cohort, reflecting the predominance of adolescent patients. Previous national poison center data have similarly reported that unintentional exploratory ingestions are more common in younger children, whereas adolescents are more likely to present following intentional self-harm [4–7]. The high rate of underlying psychiatric diagnoses in our population further underscores the vulnerability of this group. These findings highlight the importance of comprehensive psychiatric evaluation in adolescents presenting with methylphenidate overdose and reinforce the need for preventive strategies in patients with known psychiatric comorbidities. Although the overall clinical course in our cohort was favorable, several patients developed clinically significant neurological manifestations. Four patients experienced brief, self-limited seizures that resolved spontaneously without recurrence, whereas one adolescent required pharmacological treatment for seizure control. Notably, none of the patients who developed seizures had a prior history of epilepsy or seizure disorders. Although the seizure frequency observed in our cohort was higher than that reported in several poison center–based studies, most episodes were transient and associated with favorable outcomes [4, 5]. In addition, one toddler developed severe neuropsychiatric manifestations characterized by altered mental status, severe agitation, significant tachycardia, hypertension, and transient elevation of cardiac biomarkers. This case demonstrates that clinically meaningful toxicity may occur even at moderate weight-based doses, particularly in very young children and after ingestion of extended-release formulations. The temporary rise in cardiac biomarkers is consistent with reversible myocardial stress secondary to sympathomimetic overstimulation. Notably, the patient recovered fully with supportive care and close monitoring, underscoring the importance of early recognition and vigilant observation in managing pediatric stimulant intoxication. A comparable clinical course has been described in the literature [16, 17]. In a previously reported case, an 8-year-old girl who ingested 8.75 (mg/kg) of immediate-release methylphenidate developed neuropsychiatric symptoms, including agitation and psychotic features, yet achieved complete recovery with supportive treatment alone [18]. Collectively, these findings highlight that although severe manifestations are rare, careful cardiovascular and neurological monitoring remains essential, especially in younger children and in cases involving extended-release preparations. We did not identify a statistically significant association between ingested dose and the development of clinical symptoms. This finding is consistent with previous retrospective studies of oral methylphenidate overdose, which have similarly reported difficulty establishing a clear dose–response relationship [15, 19]. Although the median reported dose was higher among symptomatic patients than asymptomatic patients (7 mg/kg vs. 4 mg/kg), this difference did not reach statistical significance. Given the relatively small sample size of our study, the possibility of a type II statistical error cannot be excluded. Furthermore, all patients in our cohort had ingested at least 2 mg/kg of methylphenidate, a threshold generally considered to warrant medical evaluation following acute exposure. Variability in absorption, formulation type, individual susceptibility, and psychiatric context may influence clinical presentation more than the reported ingested dose alone. Therefore, the absence of a statistically significant association should not be interpreted as evidence that ingested dose has no influence on clinical outcomes. Rather, our findings suggest that reported ingested dose alone may not reliably predict clinical severity and should be interpreted alongside clinical presentation and other patient-specific factors. Differences between immediate-release and extended-release methylphenidate formulations may also have important implications for toxicity assessment and emergency department management [12, 13]. Compared with immediate-release preparations, extended-release formulations may be associated with delayed symptom onset, prolonged clinical effects, and a longer period of observation due to their distinct pharmacokinetic profiles [17–20]. Consequently, patients exposed to extended-release products may require extended monitoring even when initially asymptomatic. Although formulation-specific analyses were not feasible in our study, clinicians should consider the type of methylphenidate preparation when determining the duration of observation and assessing the risk of delayed toxicity. In current toxicology practice, gastric lavage is generally considered only in selected early-presenting patients with potentially serious ingestions after careful assessment of the potential risks and benefits [9]. Similarly, gastrointestinal decontamination may be considered in patients presenting shortly after ingestion of a potentially toxic dose, particularly when a substantial amount of drug has been ingested and airway protective reflexes are intact [20]. In our institution, gastric lavage and activated charcoal were considered primarily in patients presenting within the first hour after ingestion. Although gastrointestinal decontamination was associated with a numerically lower rate of symptom development in our cohort, this difference did not reach statistical significance. Given the retrospective design and limited sample size, the study was not intended to evaluate the efficacy of decontamination, and a causal relationship cannot be established. Furthermore, patients presenting earlier after ingestion may differ systematically from those presenting later, introducing potential selection bias. Therefore, our findings should not be interpreted as evidence for or against the routine use of gastrointestinal decontamination. Rather, they support an individualized approach in which supportive care and close clinical monitoring remain the cornerstone of management in pediatric methylphenidate intoxication. The toxic effects of methylphenidate are primarily mediated through inhibition of dopamine and norepinephrine reuptake transporters, resulting in increased synaptic catecholamine concentrations and sympathomimetic overstimulation [1–3]. Consequently, cardiovascular manifestations such as tachycardia and hypertension are among the most frequently reported findings, consistent with our results. Although severe complications such as hyperthermia, cardiac dysrhythmias, psychosis, rhabdomyolysis, and severe neurobehavioral disturbances were not observed in our cohort, previous reports have described these manifestations following significant methylphenidate overdose [5–7]. In the present study, the most severe manifestations included altered mental status with severe agitation, seizures, and transient cardiovascular involvement, all of which resolved completely with supportive management. These findings are consistent with the generally favorable outcomes reported in most pediatric methylphenidate intoxication series while highlighting the potential for clinically significant toxicity in selected cases [4, 19, 20]. The strengths of this study include the evaluation of isolated methylphenidate exposures and detailed clinical characterization within a tertiary pediatric emergency setting. However, several limitations should be acknowledged. The retrospective design may introduce information bias, and the relatively small sample size limits statistical power to detect associations. Reported ingested doses were based on patient or caregiver history and may be subject to recall inaccuracies. Additionally, as a single-center study, generalizability may be limited. Another important limitation is that extended-release and immediate-release methylphenidate formulations were not analyzed separately. Given potential differences in pharmacokinetics, absorption profiles, and duration of clinical effects between short-acting and long-acting preparations, the absence of formulation-based stratification could have influenced the observed symptom patterns and clinical course. Conclusion In conclusion, pediatric methylphenidate intoxication was generally associated with a favorable clinical course in our cohort, with tachycardia and mild hypertension representing the most common manifestations. While most patients experienced minor-to-moderate toxicity, severe clinical manifestations may occur and warrant careful monitoring. Supportive care and close clinical monitoring were sufficient for the management of the vast majority of patients. Future multicenter studies with larger cohorts are warranted to better define predictors of clinically significant toxicity and to optimize risk stratification strategies in pediatric methylphenidate exposure. Acknowledgements The authors have no acknowledgments to declare. Abbreviations Attention-deficit/hyperactivity disorder Emergency department Methylphenidate Interquartile range Creatine kinase–myocardial band Electrocardiogram Author contributions PY, AY, CT, and BVA contributed to the study conception and design. Material preparation, data collection, and analysis were performed by PY, AY, CT, and BVA. PY drafted the manuscript. AY and EUS provided critical revision and supervision. All authors read and approved the final manuscript. Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Data availability The datasets generated and/or analyzed during the current study are not publicly available due to the inclusion of sensitive patient information, but are available from the corresponding author on reasonable request and with permission of the institutional ethics committee. Declarations Ethics approval and consent to participate This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ege University Medical Research Ethics Committee (approval number: 25-3T/55). Due to the retrospective design of the study and the use of anonymized data, the requirement for informed consent was waived. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated and/or analyzed during the current study are not publicly available due to the inclusion of sensitive patient information, but are available from the corresponding author on reasonable request and with permission of the institutional ethics committee.